Physician profile
David B Schwalb
NPI 1528045416
$16,325.57
in general payments reported to CMS, 2019-2025
38 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,456 · 2020: $1,856 · 2021: $2,300 · 2022: $2,120 · 2023: $2,304 · 2024: $2,780 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,593.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,023.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,821.04 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Coloplast Corp | $1,693.46 | 2019-2025 | Titan |
| Amgen INC. | $1,675.67 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $966.48 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $966.09 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $934.44 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $883.55 | 2019-2025 | Eliquis, Camzyos |
| Glaxosmithkline, LLC. | $865.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $785.76 | 2021-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $548.81 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $454.02 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $386.00 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $360.67 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $306.98 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $266.67 | 2019-2025 | |
| Exact Sciences Corporation | $241.04 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $166.14 | 2019-2024 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $147.15 | 2022-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $123.00 | 2019-2025 | Capvaxive, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $101.23 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $77.67 | 2021-2025 | Gvoke Hypopen |
| Verona Pharma, INC. | $67.61 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $49.71 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $46.19 | 2021-2022 | |
| Lundbeck LLC | $45.02 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $41.89 | 2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $38.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.61 | 2021-2025 | Xifaxan |
| Genentech USA, INC. | $29.59 | 2019 | |
| Circassia INC. | $28.37 | 2019 | |
| Allergan, INC. | $27.14 | 2019 | |
| Boston Scientific Corporation | $26.56 | 2025 | General - Pain Management |
| Viatris Specialty LLC | $22.18 | 2025 | Yupelri |
| Genzyme Corporation | $21.02 | 2023 | |
| Intuity Medical INC | $19.63 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.25 | 2019 | |
| Eisai INC. | $15.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwalb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.